The mechanisms driving this resistance are complex and include both EGFR-dependent and EGFR-independent pathways. To overcome this obstacle, several therapeutic approaches have been developed for NSCLC patients who develop resistance to osimertinib [20, 21]. In the present study, TFAP2A was ...
ENTERPRISE CUSTOMERS IDENTIFY BUDGET AS A MAJOR RESTRAINING FORCE WHILE BENEFITS REMAIN ELUSIVE Country- and market-specific regulation is driving some IPv6 migration In some countries and vertical markets, IPv6 implementation has been mandated. One of the vertical examples is in financial services ...